Skip to main content

Table 1 Subject demographics and lung function

From: Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease

  Healthy Never-Smokers
(n = 17)
Asymptomatic Smokers
(n = 15)
COPD
(n = 16)
Male/Female 9/8 6/9 7/9
Age [y] 64 ± 6 62 ± 3 67 ± 7
Weight [kg] 76 ± 14 76 ± 12 72 ± 13
Height [cm] 173 ± 9 169 ± 9 170 ± 9
FEV1%pred 110 ± 15 109 ± 13 61 ± 23***
VC %pred 109 ± 20 112 ± 13 107 ± 18
FEV1/VC %pred 78.6 ± 4.0 78.4 ± 5.6 44.9 ± 14.2***
DL,CO %pred 92.0 ± 10 88.2 ± 13 60.2 ± 22***†
GOLD-stage (1/2/3/4)    3/7/5/1
  1. Data for DL,CO for one subject in the COPD group is missing
  2. ***Significance < 0.001 level
  3. Descriptive demographic data (average ± 1 standard deviation) for the subjects, lung function tests performed post bronchodilation, 1.5 mg terbutaline (Bricanyl Turbuhaler, Astra Zeneca, Mölndal, Sweden)